Back

CHA2DS2-VASc score-based anticoagulation management after catheter ablation for atrial fibrillation: a post-hoc analysis of the ALONE-AF trial

13 April 2026 (10:30 - 11:15)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulation in atrial fibrillation Oral Anticoagulation EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Young Shin Lee

Kyung Hee Medical Center, Seoul (Korea (Republic of))

4 More presentations in this session

Presentation thumbnail
Impact of kidney function on cardiovascular outcome in patients with device-detected atrial fibrillation in NOAH-AFNET 6
Professor A. Goette (Paderborn, DE)
Abstract Slides Video
Presentation thumbnail
Ablation outcome and post-interventional management of anticoagulation in patients with obesity or severe obesity and atrial fibrillation
Ms R. Bares (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Outcomes after cavotricuspid isthmus ablation: predictors of new-onset atrial fibrillation and stroke according to anticoagulation strategy
Doctor J. Villoria Martin (Huelva, ES)
Abstract Slides Video
Presentation thumbnail
Distribution of apixaban plasma concentrations across prescribed dose groups for ischemic stroke prevention in atrial fibrillation
Associate Professor K. Lim (Busan, KR)
Abstract Slides Video

Access the full session

Session thumbnail
Oral anticoagulation in atrial fibrillation

The Event

Event poster

EHRA 2026

13 April 2026 10:30 CET
You may be interested in
thumbnail
Congress Presentation
ALONE-AF: Discontinuing long-Term oral anticoagulation after successful atrial fibrillation ablation
thumbnail
Congress Presentation
Ask the Trialists - ALONE-AF
thumbnail
Congress Presentation
Rethinking anticoagulation: challenges in assessing stroke risk in atrial fibrillation patients with low CHADS-VASc scores

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources